Cite
HARVARD Citation
Philipp, S. et al. (2020). Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study. British journal of dermatology. pp. 664-672. [Online].